This report aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Therapeutics. This report contains market size and forecasts of Non-small Cell Lung Cancer Therapeutics in global, including the following market information:
Global Non-small Cell Lung Cancer Therapeutics Market Revenue, 2019-2024, 2024-2029, ($ millions)
Global top five companies in 2023 (%)
The global Non-small Cell Lung Cancer Therapeutics market was valued at US$ 9329.4 million in 2023 and is projected to reach US$ 14060 million by 2029, at a CAGR of 6.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Alimta Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-small Cell Lung Cancer Therapeutics include GlaxoSmithKline, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly and Sanofi, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-small Cell Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-small Cell Lung Cancer Therapeutics Market, by Type, 2019-2024, 2024-2029 ($ millions)
Global Non-small Cell Lung Cancer Therapeutics Market Segment Percentages, by Type, 2023 (%)
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Global Non-small Cell Lung Cancer Therapeutics Market, by Application, 2019-2024, 2024-2029 ($ millions)
Global Non-small Cell Lung Cancer Therapeutics Market Segment Percentages, by Application, 2023 (%)
Hospital
Clinic
Global Non-small Cell Lung Cancer Therapeutics Market, By Region and Country, 2019-2024, 2024-2029 ($ Millions)
Global Non-small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-small Cell Lung Cancer Therapeutics revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Non-small Cell Lung Cancer Therapeutics revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-small Cell Lung Cancer Therapeutics, market overview.
Chapter 2: Global Non-small Cell Lung Cancer Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-small Cell Lung Cancer Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-small Cell Lung Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-small Cell Lung Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-small Cell Lung Cancer Therapeutics Overall Market Size
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size: 2022 VS 2031
2.2 Global Non-small Cell Lung Cancer Therapeutics Market Size, Prospects & Forecasts: 2019-2031
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-small Cell Lung Cancer Therapeutics Players in Global Market
3.2 Top Global Non-small Cell Lung Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Non-small Cell Lung Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Non-small Cell Lung Cancer Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-small Cell Lung Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-small Cell Lung Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Non-small Cell Lung Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-small Cell Lung Cancer Therapeutics Market Size Markets, 2022 & 2031
4.1.2 Alimta
4.1.3 Iressa
4.1.4 Avastin
4.1.5 Tarceva
4.1.6 Zykadia
4.1.7 Tagrisso
4.1.8 Xalkori
4.1.9 Cyramza
4.1.10 Opdivo
4.1.11 Alecensa
4.2 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2024
4.2.2 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2024-2031
4.2.3 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-small Cell Lung Cancer Therapeutics Market Size, 2022 & 2031
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2024
5.2.2 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2024-2031
5.2.3 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
6 Sights by Region
6.1 By Region - Global Non-small Cell Lung Cancer Therapeutics Market Size, 2022 & 2031
6.2 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2024
6.2.2 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2024-2031
6.2.3 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
6.3 North America
6.3.1 By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2031
6.3.2 US Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.3.3 Canada Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.3.4 Mexico Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4 Europe
6.4.1 By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2031
6.4.2 Germany Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4.3 France Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4.4 U.K. Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4.5 Italy Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4.6 Russia Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4.7 Nordic Countries Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.4.8 Benelux Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.5 Asia
6.5.1 By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2031
6.5.2 China Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.5.3 Japan Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.5.4 South Korea Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.5.5 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.5.6 India Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.6 South America
6.6.1 By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2031
6.6.2 Brazil Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.6.3 Argentina Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2031
6.7.2 Turkey Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.7.3 Israel Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.7.4 Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
6.7.5 UAE Non-small Cell Lung Cancer Therapeutics Market Size, 2019-2031
7 Non-small Cell Lung Cancer Therapeutics Companies Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.1.4 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.1.5 GlaxoSmithKline Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.2.4 Novartis Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.2.5 Novartis Key News & Latest Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Company Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.3.4 AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.3.5 AstraZeneca Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.4.4 Roche Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.4.5 Roche Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.5.4 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.6.4 Pfizer Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.6.5 Pfizer Key News & Latest Developments
7.7 Eli Lilly
7.7.1 Eli Lilly Company Summary
7.7.2 Eli Lilly Business Overview
7.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.7.4 Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.7.5 Eli Lilly Key News & Latest Developments
7.8 Sanofi
7.8.1 Sanofi Company Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.8.4 Sanofi Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2019-2024)
7.8.5 Sanofi Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-small Cell Lung Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-small Cell Lung Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-small Cell Lung Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-small Cell Lung Cancer Therapeutics in Global Market
Table 5. Top Non-small Cell Lung Cancer Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-small Cell Lung Cancer Therapeutics Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Non-small Cell Lung Cancer Therapeutics Revenue Share by Companies, 2019-2024
Table 8. Global Companies Non-small Cell Lung Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2031
Table 12. By Type - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2031
Table 14. By Application ? Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2031
Table 15. By Application - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2031
Table 17. By Region ? Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2031
Table 18. By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2024-2031
Table 20. By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2031
Table 22. By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2031
Table 24. By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2031
Table 26. By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2031
Table 28. By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2031
Table 30. GlaxoSmithKline Company Summary
Table 31. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 32. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 33. GlaxoSmithKline Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 36. Novartis Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 37. Novartis Key News & Latest Developments
Table 38. AstraZeneca Company Summary
Table 39. AstraZeneca Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 40. AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 41. AstraZeneca Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 44. Roche Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 45. Roche Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 48. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 52. Pfizer Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 53. Pfizer Key News & Latest Developments
Table 54. Eli Lilly Company Summary
Table 55. Eli Lilly Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 56. Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 57. Eli Lilly Key News & Latest Developments
Table 58. Sanofi Company Summary
Table 59. Sanofi Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 60. Sanofi Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 61. Sanofi Key News & Latest Developments
List of Figures
Figure 1. Non-small Cell Lung Cancer Therapeutics Segment by Type in 2022
Figure 2. Non-small Cell Lung Cancer Therapeutics Segment by Application in 2022
Figure 3. Global Non-small Cell Lung Cancer Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-small Cell Lung Cancer Therapeutics Market Size: 2022 VS 2031 (US$, Mn)
Figure 6. Global Non-small Cell Lung Cancer Therapeutics Revenue, 2019-2031 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2022
Figure 8. By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 9. By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 10. By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2031
Figure 11. By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 12. By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2031
Figure 13. By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 14. By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 15. By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 16. US Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 17. Canada Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 18. Mexico Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 19. By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 20. Germany Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 21. France Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 22. U.K. Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 23. Italy Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 24. Russia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 25. Nordic Countries Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 26. Benelux Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 27. By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 28. China Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 29. Japan Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 30. South Korea Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 31. Southeast Asia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 32. India Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 33. By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 34. Brazil Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 35. Argentina Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 36. By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2019-2031
Figure 37. Turkey Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 38. Israel Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 39. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 40. UAE Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2019-2031
Figure 41. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Novartis Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Roche Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Pfizer Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Sanofi Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
